PASS Reference Set Application: Lin UW (2010) TMPRSS2-ERG-PCA-PASS
- Abbreviated Name
- PASS Ref Set App: Lin (2010) TMPRSS2-ERG
- Lead Investigator
- Lin UW, Daniel W. — University of Washington
- Coordinating Investigator
- No coordinating investigator
- Involved Investigators
Abstract
No abstract availalbe.
Aims
1. Assess the frequency of TMPRSS2:ERG gene-fusion in whole urines of an active surveillance population. 2. Evaluate urinary TMPRSS2:ERG and PCA3 levels and assess if there is a correlation with progression. 3. Evaluate longitudinal changes in urinary TMPRSS2:ERG and PCA3 levels and assess if there is a correlation with progression.
Analytic Method
Gen-Probes TMA assay
Comments
No comments available.
Outcome
In 387 men, both PCA3 and TMPRSS2:ERG scores were significantly associated with higher volume disease. For a negative repeat biopsy, and 1% to 10%, 11% to 33%, 34% or more positive cores, median PCA3, and TMPRSS2:ERG scores increased incrementally (P < 0.005). Both PCA3 and TMPRSS2:ERG scores were also significantly associated with the presence of high-grade disease. For a negative repeat biopsy, Gleason 6 and Gleason ≥7 cancers, the median PCA3, and TMPRSS2:ERG scores also increased incrementally (P = 0.02 and P = 0.001, respectively). Using the marker scores as continuous variables, the ORs for a biopsy in which cancer was detected versus a negative repeat biopsy (ref) on modeling was 1.41 (95% CI: 1.07–1.85), P = 0.01 for PCA3 and 1.28 (95% CI: 1.10–1.49), P = 0.001 for TMPRSS2:ERG.
Secure Outcome
No secure outcome available.
Publications
Biomarkers
Data Collections
- No data collections available at this time for this protocol.
- Start Date
- Jun 30 2010
- Finish Date
- Mar 20 2013
- Protocol ID
- 368
- Protocol Type
- Reference Set
- Fields of Research
-
- Proteomics
- Collaborative Group
- Prostate and Urologic Cancers Research Group
- Cancer Types
-
- Malignant neoplasm of prostate
- Phased Status
- 2